Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRQAM0)

Drug Name

Phenacetin Drug Info

Synonyms

phenacetin; 62-44-2; Acetophenetidin; N-(4-Ethoxyphenyl)acetamide; Acetphenetidin; Acetophenetidine; Acetophenetin; Phenacetine; p-Acetophenetidide; Contradouleur; Commotional; Achrocidin; Phenazetin; Contradol; Codempiral; 4'-Ethoxyacetanilide; 4-Ethoxyacetanilide; Acetamide, N-(4-ethoxyphenyl)-; p-Acetophenetidine; Fenacetina; Phenidin; Pyraphen; Phenacitin; Phenacetinum; Fenidina; Phenedina; Phenacet; Pertonal; Fenina; Phenin; Kalmin; p-Acetphenetidin; p-Acetophenetide; Phenazetina; Tetracydin; p-Ethoxyacetanilide; Stellacyl; Phenodyne; Imidazo[4,5-e][1,4]diazapine nucleotide (I)

Indication

Disease Entry	ICD 11	Status	REF
Analgesia	MB40.8	Withdrawn from market	[1]

Cross-matching ID

PubChem CID: 4754
ChEBI ID: CHEBI:8050
CAS Number: CAS 62-44-2
TTD Drug ID: DMRQAM0
VARIDT Drug ID: DR00653
INTEDE Drug ID: DR1270

Molecule-Related Drug Atlas

Molecule Type:

DTT

DME

DOT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[15]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[16]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[17]
Tiazofurin	DM5JWV9	Solid tumour/cancer	2A00-2F9Z	Approved	[18]
Mizoribine	DMW6F0S	Transplant rejection	NE84	Approved	[17]
Viramidine	DMJFNR9	Hepatitis C virus infection	1E51.1	Phase 3	[19]
VX-944	DME321B	Solid tumour/cancer	2A00-2F9Z	Phase 2	[20]
VX-148	DML32R8	Psoriasis vulgaris	EA90	Patented	[21]
PMID28074661-Compound-US20100022547C81	DMM9E1U	N. A.	N. A.	Patented	[20]
PMID28074661-Compound-US20120264760C80	DM75QVW	N. A.	N. A.	Patented	[20]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Prostaglandin G/H synthase 1 (COX-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[22]
Naproxen	DMZ5RGV	Bursitis		Approved	[23]
Mesalazine	DMOL5IU	Diverticulitis		Approved	[24]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[25]
Bromfenac	DMKB79O	Pain	MG30-MG3Z	Approved	[26]
Aminosalicylic Acid	DMENSL5	Crohn disease	DD70	Approved	[27]
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[28]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[27]
Suprofen	DMKXJZ7	Miosis	LA11.62	Approved	[29]
Gamma-Homolinolenic acid	DMSXKYG	Malnutrition	5B50-5B71	Approved	[30]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[31]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[32]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[33]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[34]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[35]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[36]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[37]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[38]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[32]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[39]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[40]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[41]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[42]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[43]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[44]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[45]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[37]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[46]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[47]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[48]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[95]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[95]
Etoricoxib	DM6A4NW	Rheumatoid arthritis	FA20	Approved	[95]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[96]
Hesperetin	DMKER83	High blood cholesterol level	5C80.00	Approved	[97]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[98]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[99]
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[100]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[101]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[102]
------------------------------------------------------------------------------------


⏷ Show the Full List of 20 Drug(s)

Drug(s) Metabolized By Cytochrome P450 2A6 (CYP2A6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[40]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[49]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[50]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[35]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[49]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[51]
Metronidazole	DMTIVEN	Abscess		Approved	[52]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[53]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[49]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[55]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[56]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[57]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[58]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[46]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[59]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[60]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[61]
Riboflavin	DM8YMWE	Acne vulgaris	ED80	Approved	[62]
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[63]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[64]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[65]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[66]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[35]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[39]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[67]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[68]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[69]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[70]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[71]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 2E1 (CYP2E1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[72]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[73]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[50]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[74]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[75]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[46]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[49]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[76]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[77]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[78]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[79]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[80]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[81]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[49]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[82]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[49]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[83]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[84]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[85]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[86]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Mephenytoin 4-hydroxylase (CYP2C19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[87]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[79]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[88]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[89]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[49]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[90]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[59]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[86]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[91]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[53]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cholesterol 24-hydroxylase (CYP46A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[9]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[9]
Dextromethorphan	DMUDJZM	Allergic rhinitis	CA08.0	Approved	[9]
Testosterone cypionate	DMC1TEV	N. A.	N. A.	Approved	[9]
ANW-32821	DMMJOZD	N. A.	N. A.	Phase 2	[92]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[9]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[9]
Dextromethorphan	DMUDJZM	Allergic rhinitis	CA08.0	Approved	[9]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[103]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[104]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[105]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[9]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[106]
ANW-32821	DMMJOZD	N. A.	N. A.	Phase 2	[9]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[107]
------------------------------------------------------------------------------------


⏷ Show the Full List of 15 Drug(s)

Drug(s) Metabolized By Cytochrome P450 2A13 (CYP2A13)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[93]
Testosterone cypionate	DMC1TEV	N. A.	N. A.	Approved	[94]
------------------------------------------------------------------------------------

Drug(s) Affected By Solute carrier family 22 member 6 (SLC22A6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[108]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[12]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[12]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[109]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[12]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[12]
Succinic acid	DMDWICP	Malnutrition	5B50-5B71	Approved	[110]
Mefenamic acid	DMK7HFI	Dysmenorrhea	GA34.3	Approved	[12]
Probenecid	DMMFWOJ	Acute gonococcal cervicitis		Approved	[111]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Organic anion transporter 7 (SLC22A9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[12]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[12]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[112]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[113]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[114]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[12]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[12]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[103]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[115]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[116]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Solute carrier family 22 member 11 (SLC22A11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[12]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[12]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[116]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[12]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[12]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[117]
Mefenamic acid	DMK7HFI	Dysmenorrhea	GA34.3	Approved	[12]
Probenecid	DMMFWOJ	Acute gonococcal cervicitis		Approved	[118]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[12]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[119]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Solute carrier family 22 member 7 (SLC22A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[12]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[120]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[113]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[121]
Allopurinol	DMLPAOB	Gout	FA25	Approved	[121]
Bumetanide	DMRV7H0	Congestive heart failure	BD10	Approved	[121]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[121]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[121]
Tetracycline	DMZA017	Acne vulgaris	ED80	Approved	[121]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[122]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Prostaglandin G/H synthase 1 (PTGS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[123]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[124]
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[125]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[126]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[127]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[128]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[129]
Bupivacaine	DM4PRFC	Anaesthesia	9A78.6	Approved	[130]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[129]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[131]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Xaa-Pro dipeptidase (PEPD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[132]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[133]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[14]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[103]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[104]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[134]
Gentamicin	DMKINJO	Bacteremia	1A73	Approved	[135]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[136]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[137]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[138]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Arylacetamide deacetylase (AADAC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[139]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[116]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[103]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[115]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[116]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[116]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[140]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[103]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[141]
Rifapentine	DMCHV4I	Pulmonary tuberculosis	1B10.Z	Approved	[141]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)	TTL7C8Q	IMDH1_HUMAN	Inhibitor	[2]
Prostaglandin G/H synthase 1 (COX-1)	TT8NGED	PGH1_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[4]
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Substrate	[4]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[5]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[6]
Cytochrome P450 1A1 (CYP1A1)	DE6OQ3W	CP1A1_HUMAN	Substrate	[7]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[6]
Cytochrome P450 2A6 (CYP2A6)	DEJVYAZ	CP2A6_HUMAN	Substrate	[6]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[8]
Cytochrome P450 2A13 (CYP2A13)	DEXZA9U	CP2AD_HUMAN	Substrate	[8]
Cholesterol 24-hydroxylase (CYP46A1)	DEKP5HX	CP46A_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Arylacetamide deacetylase (AADAC)	OT8VACT2	AAAD_HUMAN	Biotransformations	[10]
Cholesterol 24-hydroxylase (CYP46A1)	OTJ27FOX	CP46A_HUMAN	Biotransformations	[9]
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Biotransformations	[11]
Organic anion transporter 7 (SLC22A9)	OTO4BJCC	S22A9_HUMAN	Gene/Protein Processing	[12]
Prostaglandin G/H synthase 1 (PTGS1)	OTHCRLEC	PGH1_HUMAN	Gene/Protein Processing	[13]
Solute carrier family 22 member 11 (SLC22A11)	OTAJLNJZ	S22AB_HUMAN	Gene/Protein Processing	[12]
Solute carrier family 22 member 6 (SLC22A6)	OTKRCBVM	S22A6_HUMAN	Gene/Protein Processing	[12]
Solute carrier family 22 member 7 (SLC22A7)	OTKTNH1W	S22A7_HUMAN	Gene/Protein Processing	[12]
Xaa-Pro dipeptidase (PEPD)	OT3LFY7S	PEPD_HUMAN	Gene/Protein Processing	[14]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7402).
2	A potent "fat base" nucleotide inhibitor of IMP dehydrogenase. Biochemistry. 1998 Aug 25;37(34):11949-52.
3	Direct toxicity of nonsteroidal antiinflammatory drugs for renal medullary cells. Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5317-22.
4	Involvement of CYP2E1 as A low-affinity enzyme in phenacetin O-deethylation in human liver microsomes. Drug Metab Dispos. 1999 Aug;27(8):860-5.
5	Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity. J Pharm Sci. 1998 Dec;87(12):1502-7.
6	Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes. Xenobiotica. 1999 Sep;29(9):885-98.
7	Identification of CYP3A4 as the enzyme involved in the mono-N-dealkylation of disopyramide enantiomers in humans. Drug Metab Dispos. 2000 Aug;28(8):937-44.
8	CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin, and theophylline. Drug Metab Dispos. 2007 Mar;35(3):335-9.
9	Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry. 2003 Dec 9;42(48):14284-92.
10	Species differences in tissue distribution and enzyme activities of arylacetamide deacetylase in human, rat, and mouse. Drug Metab Dispos. 2012 Apr;40(4):671-9. doi: 10.1124/dmd.111.043067. Epub 2011 Dec 29.
11	A population approach to enzyme characterization and identification: application to phenacetin O-deethylation. Pharm Res. 2000 Dec;17(12):1531-6. doi: 10.1023/a:1007665310830.
12	Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002 Nov;303(2):534-9.
13	Cloning, expression, and functional characterization of human cyclooxygenase-1 splicing variants: evidence for intron 1 retention. J Pharmacol Exp Ther. 2005 Dec;315(3):1298-305.
14	Kinetic study of paracetamol on prolidase activity in erythrocytes by capillary electrophoresis with Ru(bpy)(3) (2+) electrochemiluminescence detection. Electrophoresis. 2006 Oct;27(20):4047-51. doi: 10.1002/elps.200600197.
15	Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008 Aug;64(8):753-67.
16	Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother. 2006 Jan;57(1):8-13.
17	VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci. 2001 May;90(5):625-37.
18	In vitro and in vivo antiproliferative activity of IPCAR, a new pyrazole nucleoside analog. Anticancer Res. 1998 Jul-Aug;18(4A):2623-30.
19	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
20	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
21	Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5'-monophosphate dehydrogenase inhibitor. J Pharmacol Exp Ther. 2002 Sep;302(3):1272-7.
22	The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
23	Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
24	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
25	Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
26	Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
27	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
28	Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
29	Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
30	Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.
31	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
32	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
33	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
34	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
35	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
36	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
37	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
38	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
39	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
40	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
41	Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
42	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
43	Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
44	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
45	The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
46	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
47	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
48	Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
49	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
50	Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
51	Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
52	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
53	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
54	CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
55	Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
56	Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
57	Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
58	Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
59	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
60	A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
61	Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
62	Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
63	Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
64	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
65	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
66	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
67	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
68	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
69	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
70	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
71	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
72	Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
73	Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
74	Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
75	A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
76	Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
77	Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
78	CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
79	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
80	Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
81	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
82	Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
83	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
84	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
85	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
86	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
87	High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
88	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
89	CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
90	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
91	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
92	Cholesterol-metabolizing cytochromes P450. Drug Metab Dispos. 2006 Apr;34(4):513-20.
93	Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism. J Pharmacol Exp Ther. 2006 Jan;316(1):295-303.
94	Effects of 8-methoxypsoralen on cytochrome P450 2A13. Carcinogenesis. 2005 Mar;26(3):621-9.
95	In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
96	Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
97	Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
98	Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
99	Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
100	Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
101	Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
102	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
103	Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
104	Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
105	Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
106	The molecular basis of genistein-induced mitotic arrest and exit of self-renewal in embryonal carcinoma and primary cancer cell lines. BMC Med Genomics. 2008 Oct 10;1:49.
107	Effect of aflatoxin B(1), benzo[a]pyrene, and methapyrilene on transcriptomic and epigenetic alterations in human liver HepaRG cells. Food Chem Toxicol. 2018 Nov;121:214-223. doi: 10.1016/j.fct.2018.08.034. Epub 2018 Aug 26.
108	P-gp, MRP2 and OAT1/OAT3 mediate the drug-drug interaction between resveratrol and methotrexate. Toxicol Appl Pharmacol. 2016 Sep 1;306:27-35. doi: 10.1016/j.taap.2016.06.030. Epub 2016 Jul 1.
109	Potent Inhibitors of Organic Anion Transporters 1 and 3 From Natural Compounds and Their Protective Effect on Aristolochic Acid Nephropathy. Toxicol Sci. 2020 Jun 1;175(2):279-291. doi: 10.1093/toxsci/kfaa033.
110	Lack of efflux of diglycolic acid from proximal tubule cells leads to its accumulation and to toxicity of diethylene glycol. Toxicol Lett. 2023 Apr 15;379:48-55. doi: 10.1016/j.toxlet.2023.03.007. Epub 2023 Mar 22.
111	Inhibition of organic anion transporter (OAT) activity by cigarette smoke condensate. Toxicol In Vitro. 2017 Oct;44:27-35.
112	Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
113	Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
114	Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
115	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
116	Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
117	Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor. J Steroid Biochem Mol Biol. 2016 Oct;163:77-87.
118	Neonicotinoid pesticides poorly interact with human drug transporters. J Biochem Mol Toxicol. 2019 Oct;33(10):e22379. doi: 10.1002/jbt.22379. Epub 2019 Jul 31.
119	Multiple drug transporters mediate the placental transport of sulpiride. Arch Toxicol. 2017 Dec;91(12):3873-3884. doi: 10.1007/s00204-017-2008-8. Epub 2017 Jun 9.
120	Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
121	Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
122	A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
123	Acetaminophen selectively suppresses peripheral prostaglandin E2 release and increases COX-2 gene expression in a clinical model of acute inflammation. Pain. 2007 Jun;129(3):279-86.
124	Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
125	Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem Res. 1996 Sep;21(9):995-1004.
126	Quercetin reduces oxidative damage induced by paraquat via modulating expression of antioxidant genes in A549 cells. J Appl Toxicol. 2013 Dec;33(12):1460-7. doi: 10.1002/jat.2812. Epub 2012 Sep 20.
127	Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
128	D-Penicillamine targets metastatic melanoma cells with induction of the unfolded protein response (UPR) and Noxa (PMAIP1)-dependent mitochondrial apoptosis. Apoptosis. 2012 Oct;17(10):1079-94.
129	Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
130	The differential effects of bupivacaine and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model. Anesth Analg. 2008 Jan;106(1):321-7, table of contents.
131	A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
132	Comparison of protective effect of ascorbic acid on redox and endocannabinoid systems interactions in in vitro cultured human skin fibroblasts exposed to UV radiation and hydrogen peroxide. Arch Dermatol Res. 2017 May;309(4):285-303. doi: 10.1007/s00403-017-1729-0. Epub 2017 Mar 11.
133	Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
134	Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
135	Melanin potentiates gentamicin-induced inhibition of collagen biosynthesis in human skin fibroblasts. Eur J Pharmacol. 2002 Jun 20;446(1-3):7-13. doi: 10.1016/s0014-2999(02)01793-4.
136	Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
137	Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
138	Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
139	Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
140	Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
141	Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. Biochem Pharmacol. 2011 Dec 1;82(11):1747-56.